Mizuho Reiterates Buy on Arcutis Biotherapeutics, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has reiterated a Buy rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and increased the price target from $16 to $17.

February 28, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho has reiterated a Buy rating on Arcutis Biotherapeutics and raised the price target from $16 to $17.
The reiteration of a Buy rating combined with an increased price target by a reputable analyst like Uy Ear from Mizuho is a strong positive signal for the stock. It suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100